Institute of Biomedical Stock (OTC: MRES)

Latest news for Institute of Biomedical (OTC:MRES) Stock

Institute of Biomedical Research Corp is a biomedical research and development company. The company is focused on alternative plant-based cannabinoids and mental health therapeutic research. The Institute has expanded its research to also include the augmentation of traditional medicine and the emerging science of medicinal mushrooms.

Cannabis

News

Penny Stocks

Psychedelics

Markets

CGNSF

MRES

RED LIGHT HOLLAND CORP by Red Light Holland Corp.

TRUFF

As psychedelics and AI travel their own development paths, here are some initiatives looking at ways of enhancing the former with the latter’s help.

AI-Powered Psychedelic Treatments: Special Status And Next-Gen Contests Winners

Movers & Shakers

Intraday Update

Movers

Trading Ideas

General

AAWW

ABMD

ACRGF

ACTG

ADAP

AERO

AEZS

AGGZF

AKKVF

ALBO

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALKS

ALPN

ALXEF

ANDE

ANGI

ARHN

ARLP

Adtalem Global Education Inc. Common Stock

ATGE

AUPH

AWSM

AXAS

AXDDF

BCRX

BCTXF

BIEI

BLOZF

BLOK TECHNOLOGIES INC by Blok Technologies Inc.

BLPFF

BOIVF

BOSSY

BOTY

BRTX

BSTC

BTLLF

CEIX

CERS

CHKDG

CHKDP

CHOOF

CKISF

CLDPQ

CLVS

CMCT

CMRX

CMVLF

CNONF

CNSL

COTE

CRBP

CRZBY

CSLT

CTMX

CTST

CVEO

CWRK

CYIG

DFIN

DIIBF

DKAM

DNOW

DZSI

EBKDY

ECIFY

EMESQ

ENBL

EZPW

FANG

FELP

FENG

FLMN

FRHLF

FRLI

FRNKF

FSNNQ

FTCH

FTSI

FTSV

FULC

GAIA

GARB

GARLF

GDOT

Stocks That Hit 52-Week Lows On Tuesday

Neuro-Biotech Corporation Provides Update on Latest Developments 

INSTITUTE OF BIOMED RESH by Institute of Biomedical Research Corp.

Institute of Biomedical Research Corp

As psychedelics and AI travel their own development paths, here are some initiatives looking at ways of enhancing the former with the latter&rsquo;s help.
<h3>AI-Infused Research Partnerships</h3>
The Institute of Biomedical Research Corp. (OTCMKTS: MRES) is using AI algorithms, machine learning and predictive models to conduct research on psychedelic compounds, mainly around psilocybin through funding research collaborators at the University of South Africa.&nbsp;
Meanwhile, AI mental health solutions company Cognetivity Neurosciences Ltd. (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/cgnsf#OTCQB">CGNSF</a>) has struck a deal with the Alzheimer&#39;s Society in Oman toward studying cognitive health in patients with dementia and diabetes.
Combining AI and neuroscience, the company&rsquo;s Integrated Cognitive Assessment (CognICA) platform will be used for regular monitoring of the senior population under the country&rsquo;s healthcare services, with the goal of creating a baseline performance of their&nbsp;brain health.
A secondary goal is to&nbsp;research comorbidities, like diabetes, in patients diagnosed with dementia or Alzheimer&#39;s through the use of big data toward further development of AI models that enable risk stratification and the provision of comprehensive care through tailored strategies.
<h3>3D Movement Data: &lsquo;Special&rsquo; Status, On Track For IP Coverage</h3>
Red Light Holland&rsquo;s (OTCQB: <a class="ticker" href="https://www.benzinga.com/stock/truff#OTCQB">TRUFF</a>) wholly-owned Silicon Valley-based Radix Motion has been granted the right to participate in the fast-track &ldquo;Patent Prosecution Highway&rdquo; (PPH) procedure, and has been accorded a &ldquo;special&rdquo; status for, its U.S. patent application covering the company&rsquo;s 3D movement data and AI innovations.
The patent&#39;s claims include the use of human movement data in psychedelic-assisted therapy toward promoting positive experiences and preventing negative ones, predicting and personalizing individual patient journeys, and evaluating the therapy&rsquo;s efficacy.
Further, the application also points to the new technology&rsquo;s use for real-time analysis of human movement data to identify the position&nbsp;
and body movement of a psychedelic facilitator/therapist to detect if a potential violation is taking place and, if so,&nbsp;activate real-time alerts and safety measures. As stated by the company, the new tool does not require sending or storing any video information and helps protect patient privacy.
<h3>Psychedelic Cryptography And Science Of Perception Box Winners</h3>
California-based consciousness nonprofit The Qualia Research Institute (QRI) has announced the winners of its &quot;Psychedelic Cryptography&rdquo; (PsyCrypto,) a contest calling on artists to produce videos encoded with hidden messages for people to decipher while tripping, reported <a href="https://www.vice.com/en/article/3akkd9/psychedelic-cryptography-videos-have-hidden-messages-designed-to-be-seen-while-tripping?utm_source=reddit.com">Vice</a>.
Entries were judged by members of QRI&rsquo;s international phenomenologist network. QRI&rsquo;s research director Andres Gomez-Emilsson says that only three submissions &ldquo;worked,&rdquo; according to the review experts. He said he&#39;s&nbsp;convinced that &ldquo;there are at least three to four completely new and mind-blowing ways to achieve PsyCrypto that do not use tracers at all.&rdquo;&nbsp;
In this edition, all three projects use the psychedelic experience of seeing radiant &ldquo;tracers,&rdquo; or lingering trails of colors and afterimages, to write out messages that come out as incomprehensible to a sober person.
G&oacute;mez-Emilsson predicts improved creations will begin to pop up in recreational and entertainment spaces soon, presenting stimulating opportunities for neuroscience and consciousness and changing the path of the history of&nbsp;consciousness &ldquo;in very unexpected ways.&rdquo;
Separately, the Tiny Blue Dot Foundation announced the funding of 11 neuroscientific research projects connected to &ldquo;The Science of Perception Box,&rdquo; a singular state or place the nonprofit&rsquo;s founders believe each of us lives in and whose limits can be expanded to minimize suffering and increase acceptance of self and others.
The international open call&nbsp;winners&rsquo; list includes two studies on psilocybin, one based in Vienna focusing on assessing <a href="https://www.tinybluedotfoundation.org/projects-overview#uv">the actual need</a>&nbsp;for a&nbsp;psychedelic trip &ldquo;for increased well-being and pleasure&rdquo; through fMRI brain scans, and the other based in Wisconsin adding a non-invasive transauricular vagus nerve stimulation (taVNS) to the psychedelic&rsquo;s intake for further effect enhancement, also measured through fMRI.
Photo: Benzinga edit with photo by&nbsp;geralt and&nbsp;sergeitokmakov on&nbsp;Pixabay.

CCEDF

Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB: MRES). 
In the first "Update to Shareholders," we advised shareholders of the Company's new direction as well as the list of licensed products ready to be manufactured and distributed. 
Subsequently, we revealed the description of two "Blood Tests" by first releasing a scientific account and analysis followed by a "layman s" version with explanations for common understanding. 
We have also informed the public, based on official statistics, of the commercial potential of the SymPath test in the American market. 
It is now the time to disclose the work done since the first "Update to Shareholders." 
Neuro-Biotech has to date, signed confidentiality agreements with various interested parties, including a Spanish group representing the vast majority of hospitals and private clinics in Spain. This group has shown a particular appreciation for the distribution of all our blood tests. Seeing that there is language and historical ties, all private clinics and private hospitals located in South America will be automatically granted access. 
Now if you review the list of licenses your company owns, you will notice that the last four licenses (13, 14, 15, 16), are what we call Neuroceuticals . It s actually tablets to be sold in pharmacies, that will be classified and sold as "food supplements," in order to accelerate the market penetration. There will be two concentrations; one sold "over the counter," and the other with a medical prescription. 
This fact is mentioned due to the ongoing actual negotiations with another Spanish party that controls networks of pharmacies across the country and in South America. Very soon, similar negotiations will open with large chains of pharmacies in the United States and Canada. 
We already have on hand a first order from Egypt, and we expect to conclude and receive other sales orders in the near future. The manufacturing of these tablets do not require significant capital investments such as laboratories. Fabrication will be assigned to a pharmaceutical company, already identified, responding to all our criteria and quality standards. As for cost, it remains for us to agree on the quantities to achieve economies of scale. 
Regarding our "Blood Tests," we also started preliminary discussions with chains of laboratories, in order to first, identify, evaluate and explore potential partnerships. This will avoid us having to invest in our own lab facilities in the short and medium term while ensuring the production of blood test results for health professionals to track their patients. This is exactly the same principle as a blood test ordered by your doctor to know your cholesterol levels. 
We also solicited and were contacted by various insurance companies about "SymPath." This test has been the subject of numerous scientific publications and has been evaluated in over 5,000 human subjects with consistent results of 98.8% precision. With this accuracy, the results could be enough to obtain a legal court opinion on a patient s medical status. 
The reason why insurance companies have expressed such a considerable interest is economic. As this test accurately measures the patient s condition on a scale, it avoids the sequences of "trial and error," as is currently the case in the beginning of treatment. Therefore, the health professional receiving the test results will immediately be able to precisely diagnose the patient s condition and to prescribe the proper medication. 
The immediate consequences, as you can imagine, will be a dramatic reduction of suffering for the patient, his family, his environment and accelerated healing. From a purely economic and social development standpoint, this will certainly lead to a significant reduction in lost workdays, and fewer payments from insurers and employers! Currently, without this test, it is virtually impossible for medical professional specializing in this type of disease, to separate the real from the fake patients. The whole of society will benefit from this. 
The Company will continue to provide its shareholders and investors with timely updates.

Biotech

Press Releases

African Ginger Patented for Influenza and SARS-CoV-2 Treatment: Insights from M2Bio Sciences Research Chair

MRES: M2Bio Sciences Marks Milestone Expansion with Launch of Los Angeles Office

MRES: M2Bio Sciences Expands Global Presence with New Offices in Dubai Science Park

MRES: M2MMA Gears Up for a Landmark Year in 2024

Real American Announces Appointment of Officers and Directors

MRES: M2Enviro 2023 Year-End Review and 2024 Looking Forward

MRES: M2Bio Sciences Introduces M2BioKids: A Pioneering Approach to Elevating Childhood Health and Development

MRES: M2Bio Sciences Provides Corporate Update

MRES: M2Bio Food and Beverage Wraps Up 2023/ 2024 Looking Ahead

RLAB: M2MMA Welcomes Legendary Muay Thai Icon Sagat Petchyindee to Advisory Board!

RLAB

Institute of Biomedical

As psychedelics and AI travel their own development paths, here are some initiatives looking at ways of enhancing the former with the latter&rsquo;s help.

<h3>AI-Infused Research Partnerships</h3>

The Institute of Biomedical Research Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRES#OTC">MRES</a>) is using AI algorithms, machine learning and predictive models to conduct research on psychedelic compounds, mainly around psilocybin through funding research collaborators at the University of South Africa.&nbsp;

Meanwhile, AI mental health solutions company Cognetivity Neurosciences Ltd. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CGNSF#OTCQB">CGNSF</a>) has struck a deal with the Alzheimer&#39;s Society in Oman toward studying cognitive health in patients with dementia and diabetes.

Combining AI and neuroscience, the company&rsquo;s Integrated Cognitive Assessment (CognICA) platform will be used for regular monitoring of the senior population under the country&rsquo;s healthcare services, with the goal of creating a baseline performance of their&nbsp;brain health.

A secondary goal is to&nbsp;research comorbidities, like diabetes, in patients diagnosed with dementia or Alzheimer&#39;s through the use of big data toward further development of AI models that enable risk stratification and the provision of comprehensive care through tailored strategies.

<h3>3D Movement Data: &lsquo;Special&rsquo; Status, On Track For IP Coverage</h3>

Red Light Holland&rsquo;s (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/TRUFF#OTCQB">TRUFF</a>) wholly-owned Silicon Valley-based Radix Motion has been granted the right to participate in the fast-track &ldquo;Patent Prosecution Highway&rdquo; (PPH) procedure, and has been accorded a &ldquo;special&rdquo; status for, its U.S. patent application covering the company&rsquo;s 3D movement data and AI innovations.

The patent&#39;s claims include the use of human movement data in psychedelic-assisted therapy toward promoting positive experiences and preventing negative ones, predicting and personalizing individual patient journeys, and evaluating the therapy&rsquo;s efficacy.

Further, the application also points to the new technology&rsquo;s use for real-time analysis of human movement data to identify the position&nbsp;

and body movement of a psychedelic facilitator/therapist to detect if a potential violation is taking place and, if so,&nbsp;activate real-time alerts and safety measures. As stated by the company, the new tool does not require sending or storing any video information and helps protect patient privacy.

<h3>Psychedelic Cryptography And Science Of Perception Box Winners</h3>

California-based consciousness nonprofit The Qualia Research Institute (QRI) has announced the winners of its &quot;Psychedelic Cryptography&rdquo; (PsyCrypto,) a contest calling on artists to produce videos encoded with hidden messages for people to decipher while tripping, reported <a href="https://www.vice.com/en/article/3akkd9/psychedelic-cryptography-videos-have-hidden-messages-designed-to-be-seen-while-tripping?utm_source=reddit.com">Vice</a>.

Entries were judged by members of QRI&rsquo;s international phenomenologist network. QRI&rsquo;s research director Andres Gomez-Emilsson says that only three submissions &ldquo;worked,&rdquo; according to the review experts. He said he&#39;s&nbsp;convinced that &ldquo;there are at least three to four completely new and mind-blowing ways to achieve PsyCrypto that do not use tracers at all.&rdquo;&nbsp;

In this edition, all three projects use the psychedelic experience of seeing radiant &ldquo;tracers,&rdquo; or lingering trails of colors and afterimages, to write out messages that come out as incomprehensible to a sober person.

G&oacute;mez-Emilsson predicts improved creations will begin to pop up in recreational and entertainment spaces soon, presenting stimulating opportunities for neuroscience and consciousness and changing the path of the history of&nbsp;consciousness &ldquo;in very unexpected ways.&rdquo;

Separately, the Tiny Blue Dot Foundation announced the funding of 11 neuroscientific research projects connected to &ldquo;The Science of Perception Box,&rdquo; a singular state or place the nonprofit&rsquo;s founders believe each of us lives in and whose limits can be expanded to minimize suffering and increase acceptance of self and others.

The international open call&nbsp;winners&rsquo; list includes two studies on psilocybin, one based in Vienna focusing on assessing <a href="https://www.tinybluedotfoundation.org/projects-overview#uv">the actual need</a>&nbsp;for a&nbsp;psychedelic trip &ldquo;for increased well-being and pleasure&rdquo; through fMRI brain scans, and the other based in Wisconsin adding a non-invasive transauricular vagus nerve stimulation (taVNS) to the psychedelic&rsquo;s intake for further effect enhancement, also measured through fMRI.

Photo: Benzinga edit with photo by&nbsp;geralt and&nbsp;sergeitokmakov on&nbsp;Pixabay.

Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB: MRES). 

In the first "Update to Shareholders," we advised shareholders of the Company's new direction as well as the list of licensed products ready to be manufactured and distributed. 

Subsequently, we revealed the description of two "Blood Tests" by first releasing a scientific account and analysis followed by a "layman s" version with explanations for common understanding. 

We have also informed the public, based on official statistics, of the commercial potential of the SymPath test in the American market. 

It is now the time to disclose the work done since the first "Update to Shareholders." 

Neuro-Biotech has to date, signed confidentiality agreements with various interested parties, including a Spanish group representing the vast majority of hospitals and private clinics in Spain. This group has shown a particular appreciation for the distribution of all our blood tests. Seeing that there is language and historical ties, all private clinics and private hospitals located in South America will be automatically granted access. 

Now if you review the list of licenses your company owns, you will notice that the last four licenses (13, 14, 15, 16), are what we call Neuroceuticals . It s actually tablets to be sold in pharmacies, that will be classified and sold as "food supplements," in order to accelerate the market penetration. There will be two concentrations; one sold "over the counter," and the other with a medical prescription. 

This fact is mentioned due to the ongoing actual negotiations with another Spanish party that controls networks of pharmacies across the country and in South America. Very soon, similar negotiations will open with large chains of pharmacies in the United States and Canada. 

We already have on hand a first order from Egypt, and we expect to conclude and receive other sales orders in the near future. The manufacturing of these tablets do not require significant capital investments such as laboratories. Fabrication will be assigned to a pharmaceutical company, already identified, responding to all our criteria and quality standards. As for cost, it remains for us to agree on the quantities to achieve economies of scale. 

Regarding our "Blood Tests," we also started preliminary discussions with chains of laboratories, in order to first, identify, evaluate and explore potential partnerships. This will avoid us having to invest in our own lab facilities in the short and medium term while ensuring the production of blood test results for health professionals to track their patients. This is exactly the same principle as a blood test ordered by your doctor to know your cholesterol levels. 

We also solicited and were contacted by various insurance companies about "SymPath." This test has been the subject of numerous scientific publications and has been evaluated in over 5,000 human subjects with consistent results of 98.8% precision. With this accuracy, the results could be enough to obtain a legal court opinion on a patient s medical status. 

The reason why insurance companies have expressed such a considerable interest is economic. As this test accurately measures the patient s condition on a scale, it avoids the sequences of "trial and error," as is currently the case in the beginning of treatment. Therefore, the health professional receiving the test results will immediately be able to precisely diagnose the patient s condition and to prescribe the proper medication. 

The immediate consequences, as you can imagine, will be a dramatic reduction of suffering for the patient, his family, his environment and accelerated healing. From a purely economic and social development standpoint, this will certainly lead to a significant reduction in lost workdays, and fewer payments from insurers and employers! Currently, without this test, it is virtually impossible for medical professional specializing in this type of disease, to separate the real from the fake patients. The whole of society will benefit from this. 

The Company will continue to provide its shareholders and investors with timely updates. 


-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Institute of Biomedical

News

Latest news for Institute of Biomedical (OTC:MRES) Stock

Thursday, June 08, 2023

Tuesday, October 08, 2019

Monday, November 01, 2010